Table 2 Subsequent therapies for patients who had progressive diseases after LCAR-B38M
Drugs | Number of patients | Number of patients with evaluable response | Overall response rate | CR rate |
|---|---|---|---|---|
Total | 44 | 36 | 61.1% (22/36) | 38.9% (14/36) |
Proteasome inhibitors | 23 | 20 | 80.0% (16/20) | 55.0% (11/20) |
 Bortezomib | 18 |  |  |  |
 Carfilzomib | 1 | |||
 Ixazomib | 5 | |||
Immunomodulatory drugs | 21 | 19 | 63.2% (12/19) | 36.8% (7/19) |
 Thalidomide | 5 |  |  |  |
 Lenalidomide | 12 |  |  | |
 Pomalidomide | 7 |  |  | |
Anti-CD38 mAb | 9 | 7 | 71.4% (5/7) | 42.9% (3/7) |
Anti-BCMA CAR T cells | 18 | 16 | 31.3% (5/16) | 12.5% (2/16) |